Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics

被引:11
作者
Makhinson, Michael [1 ,2 ]
机构
[1] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90506 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
antipsychotic medications; prescribing biases; schizophrenia; marketing; social psychological biases; cognitive psychological biases; CHRONIC-SCHIZOPHRENIA; DRUGS; METAANALYSIS; DEMENTIA; TRIALS; COST;
D O I
10.1097/01.pra.0000367774.11260.e4
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The shift from first-generation antipsychotic medications to second-generation antipsychotic medications initially caused a wave of excitement about the potential for improved and broader efficacy of these medications concurrent with an improved side-effect profile. Recent data from high-quality research analyses have subsequently raised significant questions about these claims. This research evidence has, however, not altered prescribing behavior in a way that would be expected from fully rational evaluation of the evidence. Prescribing decisions represent poorly understood, complex behaviors influenced by a number of external and internal forces, some of which may be elucidated by advances in social and cognitive psychology. In this article, the decision to prescribe first- versus second-generation antipsychotic medications is examined, and specific social psychological biases and individual cognitive biases are hypothesized to be significant influences on clinicians. These biases may perpetuate disparity between research evidence and clinical practice. (Journal of Psychiatric Practice 2010;16:15-21)
引用
收藏
页码:15 / 21
页数:7
相关论文
共 40 条